Search details
1.
In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies.
Int J Mol Sci
; 25(7)2024 Apr 03.
Article
in English
| MEDLINE | ID: mdl-38612803
2.
Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D.
Int J Mol Sci
; 25(10)2024 May 14.
Article
in English
| MEDLINE | ID: mdl-38791382
3.
Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2.
Int J Mol Sci
; 25(4)2024 Feb 13.
Article
in English
| MEDLINE | ID: mdl-38396898
4.
Guanylation Reactions for the Rational Design of Cancer Therapeutic Agents.
Int J Mol Sci
; 24(18)2023 Sep 07.
Article
in English
| MEDLINE | ID: mdl-37762123
5.
Clinical considerations for the design of PROTACs in cancer.
Mol Cancer
; 21(1): 67, 2022 03 07.
Article
in English
| MEDLINE | ID: mdl-35249548
6.
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.
Int J Mol Sci
; 23(10)2022 May 13.
Article
in English
| MEDLINE | ID: mdl-35628286
7.
Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation.
Int J Mol Sci
; 22(8)2021 Apr 07.
Article
in English
| MEDLINE | ID: mdl-33917174
8.
Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer.
J Cell Mol Med
; 24(5): 3117-3127, 2020 03.
Article
in English
| MEDLINE | ID: mdl-32032474
9.
Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
Int J Mol Sci
; 21(23)2020 Nov 27.
Article
in English
| MEDLINE | ID: mdl-33261142
10.
Neutrophils in cancer: prognostic role and therapeutic strategies.
Mol Cancer
; 16(1): 137, 2017 08 15.
Article
in English
| MEDLINE | ID: mdl-28810877
11.
Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal-Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities.
Cancers (Basel)
; 15(12)2023 Jun 20.
Article
in English
| MEDLINE | ID: mdl-37370859
12.
Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers.
Curr Oncol
; 30(3): 2569-2581, 2023 02 21.
Article
in English
| MEDLINE | ID: mdl-36975409
13.
Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates.
Clin Transl Med
; 13(9): e1329, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37740463
14.
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.
J Hematol Oncol
; 16(1): 118, 2023 12 12.
Article
in English
| MEDLINE | ID: mdl-38087293
15.
MZ1 co-operates with trastuzumab in HER2 positive breast cancer.
J Exp Clin Cancer Res
; 40(1): 106, 2021 Mar 19.
Article
in English
| MEDLINE | ID: mdl-33741018
16.
Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Cell Oncol (Dordr)
; 43(3): 431-444, 2020 Jun.
Article
in English
| MEDLINE | ID: mdl-32166583
17.
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Cancer Lett
; 491: 50-59, 2020 10 28.
Article
in English
| MEDLINE | ID: mdl-32735909
18.
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
J Exp Clin Cancer Res
; 38(1): 383, 2019 Aug 30.
Article
in English
| MEDLINE | ID: mdl-31470872
19.
Mapping Bromodomains in breast cancer and association with clinical outcome.
Sci Rep
; 9(1): 5734, 2019 04 05.
Article
in English
| MEDLINE | ID: mdl-30952871
20.
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.
PLoS One
; 14(4): e0209134, 2019.
Article
in English
| MEDLINE | ID: mdl-30990809